^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/26/2022
Excerpt:
Melanoma: Cutaneous...SYSTEMIC THERAPY FOR METASTATIC AND URESECTABLE DISEASE...SECOND-LINE OR SUBSEQUENT THERAPY...Useful in certain circumstances...Pembrolizumab/lenvatinib
